Currently in Tovaxin IIB Clinical Trial

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Postby Lyon » Sun Nov 26, 2006 9:39 am

00
Last edited by Lyon on Mon Jun 20, 2011 1:47 pm, edited 2 times in total.
Lyon
Family Elder
 
Posts: 6063
Joined: Wed May 03, 2006 3:00 pm

Advertisement

cool

Postby notasperfectasyou » Mon Nov 27, 2006 7:52 am

CureOrBust wrote:
notasperfectasyou wrote:ok. I'm a numbers guy. what does this really mean? It sounds like a comparison to me. They are measuring relapse reduction - is that number of exaserbations compared to prior year? Given what this therapy is saying it does, I'd prefer to see something like 90% of patients had NO relapses. The implication is that folks had exaserbations, it's just that they had fewer of them.

Going from MEMORY. In the trial where the 90% was quoted, one person had one relapse. I dont know how many people or how long the trial was for. ... see link for abstract ... It would also appear that the relapse occured in the lower dosage group.



This is really interesting. Is more than the abstract available? As I read it is does sound like only one exception. If that one exception was the 8%, then about 12 folks were in the evaluation. Do I have this right? napay
User avatar
notasperfectasyou
Family Elder
 
Posts: 774
Joined: Thu Feb 09, 2006 4:00 pm
Location: Northern Virginia

Re: cool

Postby Lyon » Mon Nov 27, 2006 1:35 pm

00
Last edited by Lyon on Mon Jun 20, 2011 1:47 pm, edited 1 time in total.
Lyon
Family Elder
 
Posts: 6063
Joined: Wed May 03, 2006 3:00 pm

Re: cool

Postby CureOrBust » Tue Nov 28, 2006 3:25 am

notasperfectasyou wrote:This is really interesting. Is more than the abstract available?


The following url gives a little more:
http://www.bcmtechnologies.com/ne_release.cfm?archive=y&id=38

All patients in the Dose 2 group had a 100% reduction in MRTC counts at the week five follow-up visit. Percentage reductions were greater in the Dose 2 group than in the Dose 1 group at every follow-up visit. Correlation between the reduction in overall MRTC frequencies and the physical component of the MSIS (p=0.0086) was strong. There was a trend to improved EDSS (p=0.0561). The annual relapse rate (ARR) for the patients prior two years before therapy was 1.28 and following therapy the ARR was 0.10 (92 percent reduction) adjusted for the number of months in the study.
User avatar
CureOrBust
Family Elder
 
Posts: 2871
Joined: Wed Jul 27, 2005 3:00 pm
Location: Sydney, Australia

Previous

Return to General Discussion

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: Brainteaser